/L (Renold et al., 1992) . The central nervous system appears to be most susceptible to toxoplasma cyst reactivation compared with other tissues where cysts are found. Between 30 and 50% of HIV positive patients infected latently with T. gondii will subsequently develop toxoplasmic encephalitis (Luft & Remington, 1992) , which is universally fatal in the absence of specific therapy. Such therapy is usually aimed at the tachyzoite or proliferative form of the organism. The cyst form of the parasite, the source of the infectious tachyzoites, is much more difficult to eradicate.
Numerous agents have potential activity against T. gondii. Drugs interfering with folate metabolism in the tachyzoites include sulphonamides (hydropteroate synthetase or HPS inhibitors) and the dihydrofolate reductase or DHFR inhibitors, trimethoprim and pyrimethamine. The latter has the greater effect on protozoa! DHFR such as malaria (Garrod, Lambert & O'Grady, 1981) . Other antifolate drugs include trimetrexate, a potent inhibitor of T. gondii DHFR, piritrexin and dapsone, an HPS inhibitor.
Several inhibitors of bacterial protein synthesis also possess anti-toxoplasma activity, probably through this same mechanism of action. These include clindamycin, spiramycin and newer macrolide drugs such as roxithromycin, clarithromycin and azithromycin. The latter has the additional advantage of activity against the cyst form of T. gondii, (Huskinson-Mark, Araujo & Remington, 1991) . Chlortetracycline, doxycycline and minocycline all show activity against T. gondii in animal models (Eyles & Coleman, 1954; Tabbara, Sakuragi & O'Connor, 1982; Chang, Comte & Pechere, 1990) .
Interference with the parasite's ability to synthesize nucleic acids provides a third mechanism of attack. Atovaquone (566C80), an antimalarial agent, is active against both the proliferative and cyst form of T. gondii (Araujo, Huskinson & Remington, 1991) . Another experimental drug in this group is arprinocid.
Immunotherapy is currently the subject of much investigation. Administration of CD8 lymphocytes, interleukin 2, interferon-gamma and -beta have shown a protective effect in experimental models (McCabe, Luft & Remington, 1984; Sharma, Hofflin & Remington, 1985; Schmitz et al., 1989; Hakim et al., 1991) .
In order to prevent TE in seropositive patients with low CD4 lymphocyte counts, a number of primary prophylactic regimens have been evaluated (Clotet et al., 1991; Koeppen et al., 1991; Jacobson et al., 1992; Ruf, Schurmann & Pohle, 1992) . Unfortunately due to a lack of large, prospective, randomized, controlled trials, they have given conflicting results. Some have shown protective capability against TE, even if there have been problems with eventual failures of prophylaxis or drug toxicity. In general, single agents have not been found to be satisfactory.
A recent review of primary prophylaxis against toxoplasmosis in HIV disease proposed that only daily sulphamethoxazole/ trimethoprim (800 mg/160 mg) or dapsone (50 mg/day)/pyrimethamine (50 mg/week) should be considered for clinical use (Landman, Hirschel & Okenshendler, 1993) . It was proposed that primary prophylaxis be given to HIV infected patients with serological evidence of exposure to toxoplasma and a CD4 lymphocyte count below 0-2xl0 9 /L. If the CD4 count was below 005 x 10 9 /L then the authors recommended prophylaxis regardless of toxoplasma antibody status because of the risk of false negative serology and primary infection.
One advantage of low dose co-trimoxazole (trimethoprim/sulphamethoxazole (160 mg/ 800 mg)) one tablet twice daily twice a week is that it combines protection against both TE and Pneumocystis carinii pneumonia (PCP) (Carr et al., 1992) . This is likely to enhance acceptability and increase patient compliance.
A recently published open, randomized, controlled trial involving 362 patients in France demonstrated that a dapsonepyrimethamine (50 mg once daily/50 mg once a week) combination drastically reduced the incidence of opportunistic toxoplasmosis as well as PCP (Girard et al., 1993) . Dapsone has a longer half-life and fewer side-effects compared with sulphonamides. Unfortunately both combinations were associated with sideeffects necessitating dose reduction or cessation of therapy; a lower dose combination (dapsone 100 mg/pyrimethamine 25 mg weekly) was ineffective (Mallolas et al., 1993) .
Standard first line therapy for acute toxoplasmosis is a combination of pyrimethamine 50-75 mg/day and sulphadiazine 4-6 g/day orally, starting with a loading dose of 100-200 mg pyrimethamine to rapidly establish high blood levels, and cpntinued for 6 weeks. These drugs act synergically against the parasite, but a high rate of side-effects leads to discontinuation of therapy in up to 45% of patients (Haverkos, 1987) ; rash and fever are the most frequent side-effects. Patients with AIDS who suffer from sulphonamide induced rashes may be successfully desensitized (Tenant-Flowers et al., 1991) , and these drugs should not be stopped prematurely. Folinic acid (leucovorin), at a dose of at least 10 mg/day orally should be administered concurrently to counteract the toxic effect of pyrimethamine on the bone marrow. Haematotoxicity is potentiated by antiretroviral drugs which should be avoided during acute therapy. In addition, zidovudine may have an antagonistic effect on pyrimethamine (Israelski, Tom & Remington, 1989) . Sulphonamides may also produce a number of nephrotoxic side-effects such as crystalluria, haematuria, and renal failure. These are managed by rehydration, urinary alkalinization and dose reduction (Simon, Brosius & Rothstein, 1990) .
Patients who are intolerant of sulphonamides may be treated with a combination of pyrimethamine and clindamycin (1200-4800 mg/day) orally or intravenously. Two prospective, controlled studies (Katlama, 1991 (preliminary findings); Dannemann et al., 1992) , have shown this combination to be comparable with pyrimethamine/ sulphonamides, although side effects due to clindamycin and requiring discontinuation of therapy, were seen in 30% of patients; these included skin rash, neutropenia and gastrointestinal disturbance, especially diarrhoea. Pseudomembranous colitis may occur rarely.
Alternative drug combinations which may be of use in the management of acute toxoplasmosis include sulphamethoxazole and trimethoprim (Canessa et al., 1992) , pyrimethamine and clarithromycin (Fernandez-Martin et al., 1991) , pyrimethamine and azithromycin (Saba et al., 1992) , pyrimethamine and doxycycline (Hagberg, Palmertz & Lindberg, 1993) , clindamycin and 5-fluoro-uracil (Dhiver et al., 1993) , and atovaquone monotherapy (Kovacs et al., 1992) . No large scale clinical study has validated any of these regimens so far.
Following treatment of acute toxoplasmosis, patients will almost always relapse unless they are given life-long maintenance therapy (Cohn et al., 1989) because of the inability of most of these drugs to destroy the cyst form of the parasite. Maintenance therapy consists of 25-50 mg pyrimethamine and 2-4 g sulphadiazine daily (Leport el al., 1988) . Patients unable to tolerate higher doses of sulphonamides during the acute treatment phase may still be successfully managed on this regimen which also has the advantage of preventing PCP. If sulphonamides are contraindicated pyrimethamine (25 mg/day) and clindamycin (at least 1200 mg/day) may be given (Remington & Vilde, 1991; Uberti Foppa et al., 1991) . It appears that intermittent (twice weekly) therapy with pyrimethamine and sulphadiazine (Pedro! et al., 1990) , or high dose pyrimethamine (50 mg/day) alone (de Gans et al., 1992) , may also be effective as chronic suppressive therapy. Other alternatives include pyrimethamine plus dapsone and atovaquone monotherapy.
There is no doubt that as the number of patients with AIDS increases worldwide, acute toxoplasmosis and its primary prevention, treatment and secondary prevention will become more important. At present, the choice of therapy for each situation is made difficult by the lack of large, properly controlled trials demonstrating efficacy. Most of the available drugs are beset with problems of side-effects and patients may eventually refuse treatment altogether (Pedrol el al., 1990) . There is a need for new, well tolerated antitoxoplasmic agents and especially those with anti-cyst activity, whereby it may be possible to eradicate the organism completely, thus removing the need for suppressive therapy.
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